SEC Form 4Coverage since Jun 29, 2026
$CADL insider trading
Over the last 12 months, Candel Therapeutics insiders reported no purchases and 2 sales totaling $306K across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $306K 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $CADL · 12Mvia TradingView
Top insiders · 12m
Tyagarajan SeshuChief Technology Officer1× · $70K
Barone FrancescaChief Scientific Officer1× · $236K
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Barone FrancescaChief Scientific Officer · O | ▼ Sale | 23,447 | $10.06 | $236K | -23.3% | plan |
| Jun 29, 2026 | Tyagarajan SeshuChief Technology Officer · O | ▼ Sale | 7,000 | $10.02 | $70K | -7.7% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CADL feed.